60 DEGREES PHARMA INC (SXTP) Fundamental Analysis & Valuation

NASDAQ:SXTP • US83006G5009

Current stock price

1.51 USD
+0.01 (+0.67%)
At close:
1.5293 USD
+0.02 (+1.28%)
After Hours:

This SXTP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SXTP Profitability Analysis

1.1 Basic Checks

  • In the past year SXTP has reported negative net income.
  • In the past year SXTP has reported a negative cash flow from operations.
  • SXTP had negative earnings in each of the past 5 years.
  • In the past 5 years SXTP always reported negative operating cash flow.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • SXTP's Return On Assets of -126.70% is on the low side compared to the rest of the industry. SXTP is outperformed by 80.21% of its industry peers.
  • With a Return On Equity value of -191.31%, SXTP is not doing good in the industry: 74.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -126.7%
ROE -191.31%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • SXTP has a better Gross Margin (42.47%) than 62.50% of its industry peers.
  • In the last couple of years the Gross Margin of SXTP has declined.
  • The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SXTP Health Analysis

2.1 Basic Checks

  • SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SXTP has more shares outstanding
  • SXTP has a worse debt/assets ratio than last year.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50K 100K
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • SXTP has an Altman-Z score of -12.17. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
  • SXTP's Altman-Z score of -12.17 is on the low side compared to the rest of the industry. SXTP is outperformed by 75.00% of its industry peers.
  • SXTP has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • SXTP has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -12.17
ROIC/WACCN/A
WACC9.35%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • SXTP has a Current Ratio of 2.87. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SXTP (2.87) is comparable to the rest of the industry.
  • A Quick Ratio of 2.63 indicates that SXTP has no problem at all paying its short term obligations.
  • SXTP has a Quick ratio of 2.63. This is comparable to the rest of the industry: SXTP outperforms 53.13% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.63
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SXTP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 61.25% over the past year.
  • The Revenue has grown by 192.74% in the past year. This is a very strong growth!
  • Measured over the past years, SXTP shows a very negative growth in Revenue. The Revenue has been decreasing by -52.49% on average per year.
EPS 1Y (TTM)61.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.81%
Revenue 1Y (TTM)192.74%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%291.53%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.93% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, SXTP will show a very strong growth in Revenue. The Revenue will grow by 48.16% on average per year.
EPS Next Y91.48%
EPS Next 2Y39.78%
EPS Next 3Y25.93%
EPS Next 5YN/A
Revenue Next Year164.27%
Revenue Next 2Y81.47%
Revenue Next 3Y82.46%
Revenue Next 5Y48.16%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. SXTP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SXTP's earnings are expected to grow with 25.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.78%
EPS Next 3Y25.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SXTP Dividend Analysis

5.1 Amount

  • SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SXTP Fundamentals: All Metrics, Ratios and Statistics

60 DEGREES PHARMA INC

NASDAQ:SXTP (3/30/2026, 8:00:01 PM)

After market: 1.5293 +0.02 (+1.28%)

1.51

+0.01 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)N/A
Inst Owners4.09%
Inst Owner Change4.14%
Ins Owners1.39%
Ins Owner Change2.1%
Market Cap1.95M
Revenue(TTM)1.35M
Net Income(TTM)-8.48M
Analysts82.5
Price Target17.95 (1088.74%)
Short Float %7.66%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.43%
Min EPS beat(2)-27.66%
Max EPS beat(2)46.52%
EPS beat(4)1
Avg EPS beat(4)-61.15%
Min EPS beat(4)-247.17%
Max EPS beat(4)46.52%
EPS beat(8)2
Avg EPS beat(8)-34.36%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.91%
Min Revenue beat(2)0.28%
Max Revenue beat(2)29.55%
Revenue beat(4)2
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-29.6%
Max Revenue beat(4)29.55%
Revenue beat(8)2
Avg Revenue beat(8)-18.2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)300%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-300%
EPS NY rev (1m)0%
EPS NY rev (3m)-287.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.44
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-70.68
EYN/A
EPS(NY)-7.04
Fwd EYN/A
FCF(TTM)-5.33
FCFYN/A
OCF(TTM)-5.27
OCFYN/A
SpS1.05
BVpS3.43
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -126.7%
ROE -191.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.47%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 112.77%
Cap/Sales 6.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.63
Altman-Z -12.17
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.81%
EPS Next Y91.48%
EPS Next 2Y39.78%
EPS Next 3Y25.93%
EPS Next 5YN/A
Revenue 1Y (TTM)192.74%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%291.53%
Revenue Next Year164.27%
Revenue Next 2Y81.47%
Revenue Next 3Y82.46%
Revenue Next 5Y48.16%
EBIT growth 1Y16.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-47.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.49%
OCF growth 3YN/A
OCF growth 5YN/A

60 DEGREES PHARMA INC / SXTP Fundamental Analysis FAQ

What is the fundamental rating for SXTP stock?

ChartMill assigns a fundamental rating of 2 / 10 to SXTP.


What is the valuation status of 60 DEGREES PHARMA INC (SXTP) stock?

ChartMill assigns a valuation rating of 1 / 10 to 60 DEGREES PHARMA INC (SXTP). This can be considered as Overvalued.


What is the profitability of SXTP stock?

60 DEGREES PHARMA INC (SXTP) has a profitability rating of 1 / 10.


What is the earnings growth outlook for 60 DEGREES PHARMA INC?

The Earnings per Share (EPS) of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 91.48% in the next year.